

Data Sharing Statement

Sadoff J, Le Gars M, Shukarev G, et al. Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine. *N Engl J Med*. DOI: 10.1056/NEJMoa2034201.

Question	Authors' Response
Will the data collected for your study be made available to others?	No
Would you like to offer context for your decision?	These are interim data from an ongoing study.
Which data?	—
Additional information about data	—
How or where can the data be obtained?	—
When will data availability begin?	—
When will data availability end?	—
Will any supporting documents be available?	—
Which supporting documents?	—
Additional information about supporting documents	—
How or where can supporting documents be obtained?	—
When will supporting documents availability begin?	—
When will supporting documents availability end?	—
To whom will data be available?	—
For what type of analysis or purpose?	—
By what mechanism?	—
Any other restrictions?	—
Additional information	—

This statement was posted on January 13, 2021, at NEJM.org.